Pharmaceutical Working Group Position Paper 2016/2017 - 制药工作组建议书2016/2017 Go back »


The Pharmaceutical Working Group represents over 50 foreign pharmaceutical manufacturing companies operating in China. The working group encourages government policies that support the creation of a sustainable system that fosters innovation and healthy growth of the pharmaceutical industry as a whole, while improving patient access to innovative, highquality medicines, in line with China's declared strategic objectives for the healthcare sector. Policies related to intellectual property (IP), pricing and reimbursement are potentially the most useful tools for rewarding quality and safety while creating incentives for domestic and multinational companies alike to bring innovative medicines to the Chinese market. The working group supports the establishment of a transparent regulatory environment whereby the solicitation of comments and participation from the pharmaceutical industry (both local and foreign) form an integral part of policy setting, particularly on issues such as pricing, reimbursement and intellectual property rights (IPR) .

Related documents

Position Paper 2016/2017 - 欧盟企业在中国建议书2016/2017

Quality and Safety Services Working Group Position Paper 2016/2017 - 质量与安全子工作组建议书2016/2017

Investment Working Group Position Paper 2016/2017 - 投资工作组建议书2016/2017

Related EURObiz articles